---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-045714"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T08:46:30.338855+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma shareholders approve reverse stock split authorization at ratio of 1:5 to 1:30

## Summary
- Special meeting on Dec 18, 2023; 58.13% of outstanding shares voted.
- Proposal passed with 20.3M for, 3.8M against, 17k abstain.
- Board has discretion to set final ratio within 1-for-5 to 1-for-30 range.
- Reverse split authorization is part of charter amendment to be announced publicly.

## SEC filing metadata
- accession: 0001493152-23-045714
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315223045714/0001493152-23-045714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315223045714/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-045714
- JSON: https://secwatch.observer/filing/0001493152-23-045714.json
- Plain text: https://secwatch.observer/filing/0001493152-23-045714.txt

## Key facts
- Shareholder Votes
  GT Biopharma, Inc. shareholders approved Reverse stock split at ratio between 1-for-5 to 1-for-30 at the 2023-12-18 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-12-18
  source text: Proposal to approve an amendment to the Registrant’s second restated certificate of incorporation, as amended, to effect a reverse stock split with respect to the Registrant’s issued and outstanding common stock, par value $0.001 per share, at a ratio between 1-for-5 to 1-for-30, or the Range, with the ratio within such Range to be determined at the discretion of the Board without further approval or authorization of the Registrant’s stockholders and included in a public announcement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000149315223045714/0001493152-23-045714-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.